“The European financial crisis is creating a tug-of-war between the pharmaceutical industry and governments as austerity measures from the U.K. to Germany clamp down on reimbursements, especially for new drugs.
GlaxoSmithKline Plc (GSK) and Boehringer Ingelheim GmbH are among drugmakers delaying introductions or partially withdrawing their products in some European markets as governments raise the bar on what they’re willing to cover.”
If you enjoy the content at iBankCoin, please follow us on Twitter